Dow Up0.48% Nasdaq Up0.43%

BioSpecifics Technologies Corp. (BSTC)

29.33 0.02(0.07%) Aug 19, 4:00PM EDT
ProfileGet Profile for:
BioSpecifics Technologies Corp.
35 Wilbur Street
Lynbrook, NY 11563
United States - Map
Phone: 516-593-7000
Fax: 516-593-7039

Index Membership:N/A
Full Time Employees:5

Business Summary 

BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren’s contracture and Peyronie’s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on BioSpecifics Technologies Corp.

Corporate Governance 
BioSpecifics Technologies Corp.’s ISS Governance QuickScore as of Jul 1, 2013 is 8. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 7.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Thomas L. Wegman , 59
Chief Exec. Officer, Pres, Principal Financial Officer, Principal Accounting Officer, Sec., Director, Pres of ABC-Curacao, Pres of ABC-New York, Sec. of ABC-Curacao, Sec. of ABC-New York, Director - ABC-Curacao and Director of ABC-New York
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders